



Antimicrobial resistance: Current and

emerging threats

Dr Deborah Williamson BSc MBChB MRCP FRCPA PhD Deputy Director, Microbiological Diagnostic Unit Public Health Laboratory Doherty Institute, University of Melbourne






Overview

- Combating AMR in Australia and NZ
- Current and emerging AMR threats in NZ



- Threatens the effective prevention and treatment of a wide range of infections caused by bacteria, parasites, viruses, fungi
- Higher morbidity, mortality, healthcare costs
- Critical threat to global public health





CDC Threat Levels

Urgent










U.S. Department of Health and Human Services Centers for Disease Control and Prevention

Serious












others



One Health Issue



Source: GAO Report Antibiotic Resistance, 2011


GLOBAL ACTION PLAN

ON ANTIMICROBIAL RESISTANCE






Action Agenda for Antimicrobial Resistance in the Western Pacific Region







RESPONDING TO THE THREAT OF antimicrobial resistance



Australia's First National Antimicrobial Resistance Strategy 2015-2019

June 2015

Australian Response

Objective One

Increase awareness and understanding of antimicrobial resistance, its implications and actions to combat it, through effective communication, education, and training

Objective Two

Implement effective antimicrobial stewardship practices across human health and animal care settings to ensure the appropriate and judicious prescribing, dispensing and administering of antimicrobials

Objective Three

Develop nationally coordinated One Health surveillance of antimicrobial resistance and antimicrobial usage

Objective Four

Improve infection prevention and control measures across human health and animal care settings to help prevent infections and the spread of resistance

Objective Five

Agree a national research agenda and promote investment in the discovery and development of new products and approaches to prevent, detect and contain antimicrobial resistance

Objective Six

Strengthen international partnerships and collaboration on regional and global efforts to respond to antimicrobial resistance

Objective Seven

Establish and support clear governance arrangements at the local, jurisdictional, national and international levels to ensure leadership, engagement and accountability for actions to combat antimicrobial resistance



National Alert System for Critical Antimicrobial Resistances

Species	Critical Resistance (as at September 2015)		
Enterobacteriaceae	Carbapenemase-producing strains Ribosomal methylases-producing strains		
Enterococcus species	Linezolid non-susceptible		
Mycobacterium tuberculosis	MDR (rifampicin resistant) strains		
Neisseria gonorrhoeae	Ceftriaxone non-susceptible strains		
Salmonella species	Ceftriaxone non-susceptible strains		
Shigella species	MDR strains		
Staphylococcus aureus	Vancomycin, linezolid or daptomycin non-susceptible		
Streptococcus pyogenes	Penicillin reduced susceptibility		



Draft Victorian Guidelines on Carbapenemase-producing Enterobacteriaceae


For Health Services November 2015



 Routine genomics for characterisation of new **CRE** isolates in Victoria

 Will contribute to decisions regarding determination of risk status and interventions

Department of Health & Human Services





Public Health Surveillance

Information for New Zealand Public Health Action

Antimicrobial Resistance

SITE CONTENTS

- Home
- Public Health Surveillance
- Surveillance Reports
- EpiSurv
- LabSurv

Antimicrobial Resistance


- Acquired carbapenemases in Enterobacteriaceae
- Campylobacter
- ESBLs in Enterobacteriaceae
- <u>General</u> antimicrobial <u>susceptibility data</u>
- Group A streptococci
- Haemophilus influenzae from invasive disease
- MRSA: Annual <u>Reports</u>
- MRSA: Weekly <u>Reports</u>
 Neisseria

for the national surveillance of antimicrobial resistance among human pathogens. Data from various surveillance systems and sources is used to compile national antimicrobial resistance data:

The Antibiotic Reference Laboratory at ESR is responsible

- Antimicrobial susceptibility data generated from routine diagnostic susceptibility testing in hospital and community laboratories is collected and analysed.
- The antimicrobial susceptibility of bacterial isolates referred to ESR for further investigation, such as epidemiological typing, is monitored. This surveillance includes *Salmonella*, and invasive isolates of *Streptococcus pneumoniae*, *Neisseria meningitidis* and *Haemophilus influenzae*.
- Periodic point-prevalence surveys of antimicrobial susceptibility among a specific organism using a purpose-collected sample of isolates from throughout the country are conducted.
- Rare and emerging resistant bacteria are monitored by requesting hospital and community laboratories to refer all such isolates to ESR. Currently this surveillance includes bacteria, especially Enterobacteriaceae, with acquired carbapenemases, vancomycin-resistant Enterococci and vancomycin non-susceptible Staphylococcus aureus.

Data from this surveillance is routinely published on this website.



Tuesday 31st January 2017

E/S/R

survqueries@esr.cri.nz to be notified when reports are published. Please specify the reports you are interested in:

- NZ Public Health Surveillance Report
- Monthly Surveillance Report
- Annual Surveillance Summary
- Annual Summary of Outbreaks
- Annual STI Report
- Quarterly STI Clinic Report
- Quarterly STI Lab Report

For the Weekly Influenza Update report please check <u>here</u> each Thursday.

Specific AMR threats in NZ

<u>'Global'</u>

- Carbapenem-resistant
 Enterobacteriaceae
- ESBL-producing
 Enterobacteriaceae
- Resistant *Neisseria* gonorrhoeae
- MDR-TB / XDR-TB

<u>'Home-grown'</u>

- Staphylococcus aureus and topical antimicrobial resistance
- Co-resistant
 Campylobacter jejuni
- Livestock-associated MRSA

Specific AMR threats in NZ


<u>'Global'</u>

- Carbapenem-resistant
 Enterobacteriaceae
- ESBL-producing
 Enterobacteriaceae
- Resistant Neisseria gonorrhoeae
- MDR-TB / XDR-TB

<u>'Home-grown'</u>


- Staphylococcus aureus and topical antimicrobial resistance
- Co-resistant *Campylobacter jejuni*
- Livestock-associated MRSA

Antimicrobial resistance in New Zealand



Antimicrobial resistance


Total antibiotic consumption (J01) in the NZ community



JAC, 2016

E/S/R

Comparison of antibiotic consumption with EU and OECD countries




JAC, 2016

E/S/R



A fusidic acid-resistant ST5 clone has emerged as

the dominant MRSA clone in New Zealand





Kids' skin cream spawns superbug

STACEY KIRK AND DONNA-LEE BIDDLE Last updated 06:23, March 18 2015



The treatment of childhood skin infections with antibiotic ointment is driving the spread of hospital superbugs, putting lives at risk, infectious disease experts warn.

Doctors are calling for urgent action to regulate

its use, amid new research which shows children are being over-prescribed antibiotic cream, leading to a "home grown" strain of the deadly bug MRSA.

"Our current use of topical antibiotics is endangering our antibiotic supply and putting lives at risk," said clinical microbiologist and lead researcher Deborah Williamson, from the University of Otago.

"We need to halt its unregulated use immediately before it's too late."

MRSA is a multi-drug-resistant strain of the common infection staphylococcus aureus. It's what is known as a "superbug", which can make minor infections and injuries deadly, because the antibiotics used to treat it no longer work.

ê R	NZ		LISTEN L	IVE: <u>NATIONAL</u> CONCERT
НОМЕ	NEWS	NATIONAL	CONCERT	PACIFIC
NEW ZEALAN	ND WORLD POLI	TICS PACIFIC TE AO M	1āori sport	BUSINESS COMMENT &
Skin a 11:19 am on 18		se linked to) spread G• 😳 in 🖂
There are	warnings the tre	atment of children'	s skin infectior	ns with antibiotic

ointment is driving the spread of hospital superbugs and putting lives at risk.

Research sounding the alarm over the use of the ointment, called fusidic acid, has been presented to scientists attending the annual Australasian Society for Infectious Diseases meeting in Auckland today.

New Zealand has one of the highest incidences in the developed world of Staphylococcus Aureus, which causes the superbug, MRSA.

It presents in children as school sores, boils and crusty ulcers which doctors commonly treated with the ointment.



Ointment fusidic acid linked to MRSA superbug rise

By Heather McCracken

5:00 AM Wednesday Mar 18, 2015

Health Hospitals Pharmaceuticals


★ **f** 913 **y** 0 in 0 8+2

Use of a common antibiotic lowers resistance and could mean minor ailments once again become killers.





fusC is invariably contained within SCC elements




Likely reason for why FA seems to be driving the emergence of MRSA

• Co-selection of *fusC* and *mecA*




Population Structure of FA^R CC5 Isolates





Closely related to ST5 MSSA isolates FA^R clone possibly emerged from locally circulating MSSA

> Baines S.....Williamson DA AAC, 2016 * Ellington M et al. IJAA, 2015











Conclusions

- AMR is one of the biggest public health threats of the modern age
- It is almost exclusively a 'man-made' problem
- There are AMR issues 'unique' to NZ which are preventable and reducable
- Local, national and international collaboration is key